Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer
| العنوان: | Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer |
|---|---|
| المؤلفون: | David Aguiar-Bujanda, Juana Oramas, Ana Laura Ortega-Granados, Aspet Study Investigators, Raquel Galán, Jose Manuel Trigo, Juana Campillo Fuentes, Javier de Castro, José Luis Fírvida, Rocío Gordo, Ángel Artal-Cortes |
| المصدر: | Anticancer Research. 39:1317-1328 |
| بيانات النشر: | Anticancer Research USA Inc., 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, biology, business.industry, First line, General Medicine, Disease, medicine.disease, Asymptomatic, respiratory tract diseases, Metastasis, Internal medicine, Re biopsy, medicine, biology.protein, Epidermal growth factor receptor, Erlotinib, medicine.symptom, Lung cancer, business, neoplasms, medicine.drug |
| الوصف: | Aim To assess the patterns of disease progression in advanced/metastatic epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) on first-line treatment with erlotinib and identify potential prognostic factors for progression-free survival (PFS). Patients and methods Patients with stage IIIB/IV EGFR-mutation-positive NSCLC receiving first-line erlotinib were followed-up until 24 months after the last patient was enrolled or until premature withdrawal for any cause. Results A total of 127 evaluable patients were enrolled. The median PFS and overall survival were 8.8 and 19.1 months, respectively. Disease progression was asymptomatic in 57.6% of patients and 53.3% developed new sites of metastasis. The presence of liver metastasis was identified as an independent prognostic factor for poor PFS. Conclusion Metastatic progression with asymptomatic disease seems to be the predominant pattern of disease progression on first-line erlotinib in real-life practice in patients with advanced/metastatic EGFR-mutant NSCLC. Additionally, the presence of liver metastases may negatively affect PFS in these patients. |
| تدمد: | 1791-7530 0250-7005 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::f553506a226131ed446329b09e0435d8 https://doi.org/10.21873/anticanres.13244 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi...........f553506a226131ed446329b09e0435d8 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17917530 02507005 |
|---|